Skip to main
  1. Stocks
  2. uniQure
  3. Forecast
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 42%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

uniQure is viewed favorably because its lead Huntington’s disease program, AMT-130, has shown meaningful slowing across multiple endpoints, with statistically significant benefits on TFC in the 3-year data and supportive signals despite the mixed 4-year read. The fundamental thesis is strengthened by a notably more constructive FDA backdrop, as the agency now appears open to a BLA based on the 3-year data and a confirmatory study using standard of care rather than sham surgery, which materially lowers regulatory and operational risk. Support also comes from a proven gene-therapy execution record, a first-in-class Hemophilia B asset with 37% FIX activity versus about 20% for PFE, and promising pipeline progress in mTLE and Fabry.

Bears say

uniQure is facing a highly uncertain investment case because its value depends on successful execution across multiple risky programs while also navigating commercial launch delays for HEMGENIX. Clinical setbacks in Huntington’s disease, SOD1 ALS, and temporal lobe epilepsy, along with regulatory uncertainty, intellectual property risk, and the possibility of safety signals or failure to show sustained efficacy, could materially undermine the pipeline. Competitive pressure from PFE, IONS, and WVE, plus long-term pricing pressure on HEMGENIX, further weakens the fundamental outlook and raises the risk that future commercialization and returns disappoint.

uniQure (QURE) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 42% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

uniQure (QURE) Analyst Forecast & Price Prediction

Get the latest uniQure (QURE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in uniQure (QURE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 12 analysts, uniQure (QURE) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


uniQure (QURE) Analyst Forecast & Price Prediction

Get the latest uniQure (QURE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in uniQure (QURE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover QURE stock data and trends